East London Sickle Cell Disease Neonatal Cohort

  • Research type

    Research Study

  • Full title

    Long-term follow-up of the East London Sickle Cell Disease Neonatal Cohort

  • IRAS ID

    217010

  • Contact name

    PAUL Telfer

  • Contact email

    paul.telfer@bartshealth.nhs.uk

  • Sponsor organisation

    Barts Health NHS Trust

  • Duration of Study in the UK

    0 years, 11 months, 31 days

  • Research summary

    Sickle Cell Disease is the commonest genetic condition in England, affecting predominantly black African and Caribbean subjects. Although a single gene disorder, the condition is variable in severity and results in a panoply of acute and chronic complications, reduced life expectancy, poor quality of life and large demands on health care services. The disease is not well understood particularly with regard to long-term natural history and definition of risk factors which might help in guiding therapy. The E London Newborn cohort is a unique cohort of patients diagnosed with universal newborn screening in the London Boroughs of Hackney since 1983. The cohort is under continuous clinical follow up at The Royal London Hospital, although a minority have transferred care to other clinics or become lost to follow-up. The first report on the cohort was published in 2007. After a further decade of follow-up, an analysis of outcomes and risk factors will provide important data to inform health service planning and treatment decisions for SCD in the UK and elsewhere. The current study will require collecting and validating clinical, laboratory and radiological data on all cohort patients, and undertaking a number of statistical analyses on the dataset. Data on patients under current follow-up at RLH is maintained on a secure clinical database at RLH. Information on patients in other clinics will need to be sought from their GP or specialist. Attempts will be made to trace those lost to follow-up. In order to avoid bias and to enable an accurate assessment of overall outcomes, we wish to use non-consented patient data and will be applying to REC and the Confidentiality Advisory Group

  • REC name

    London - Bloomsbury Research Ethics Committee

  • REC reference

    17/LO/0281

  • Date of REC Opinion

    8 Mar 2017

  • REC opinion

    Favourable Opinion